[Frontiers in Bioscience 1, e34-41, July 1, 1996]
Reprints
PubMed
CAVEAT LECTOR



PIG alpha1,3GALACTOSYLTRANSFERASE: A MAJOR TARGET FOR GENETIC MANIPULATION IN XENOTRANSPLANTATION

Karen Strahan, Andrew Preece and Kenth Gustafsson

Division of Cell & Molecular Biology, Institute of Child Health, University of London, 30 Guilford St., London WC1N 1EH, UK

Received 06/21/96; Accepted 07/02/96; On-line 07/08/96

8. REFERENCES

1. H. J. Auchincloss: Xenogeneic transplantation: A review. Transplantation 46, 1-20 (1988)

2. H. J. Auchincloss: Xenografting: A review. Transplant Rev 4, 14-27 (1990)

3. J. L. Platt, G. M. Vercelotti, A. P. Dalmasso, A. J. Matas, R. M. Bolman, J. S. Najarian, & F. H. Bach: Transplantation of discordant xenografts: a review of progress. Immunol Today 11, 450-6 (1990)

4. F. H. Bach, A. P. Dalmasso, & J. L. Platt: Xenotransplantation: A current perspective. Transplant Rev 6, 163-74 (1992)

5. R. J. Brewer, M. J. Del-Rio, M. S. Roslin, M. Sadeghian, Z. Zisbrod, J. H. Burack, J. N. Cunningham, & A. J. Norin: Depletion of preformed antibody in primates for discordant xenotrans-plantation by continuous donor organ plasma perfusion. Transplant Proc 25, 385-6 (1993)

6. T. J. Kroshus, A. P. Dalmasso, J. R. Leventhal, R. John, A. J. Matas, & R. M. Bolman IIId: Antibody removal by column immunoabsorption prevents tissue injury in an ex vivo model of pig-to-human xenograft hyperacute rejection. J Surg Res 59, 43-50 (1995)

7. J. R. Leventhal, R. John, J. P. Fryer, J. C. Witson, J. M. Derlich, & J. Remiszewski: Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation 59, 294-300 (1995)

8. K. R. McCurry, D. L. Kooyman, C. G. Alvarado, A. H. Cotterell, M. J. Martin, J. S. Logan, & J. L. Platt: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1, 423-7 (1995)

9. A. M. Rosengard, N. R. Cary, G. A. Langford, A. W. Tucker, J. Wallwork, & D. J. White: Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Transplantation 59, 1325-33 (1995)

10. M. S. Sandrin, W. L. Fodor, E. Mouhtouris, N. Osman, S. Cohney, S. A. Rollins, E. R. Guilmette, E. Setter, S. P. Squinto, & I. F. C. McKenzie: Enzymatic remodelling of the carbohydrate surface of xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1, 1261-7 (1995)

11. R. T. Calne: Organ transplantation between widely discordant species. Transplant Proc 2, 550-1 (1970)

12. J. L. Platt, R. J. Fischel, A. J. Matas, S. A. Reif, R. Morton Bolman, & F. H. Bach: Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 52, 214-9 (1991)

13. K. M. Strahan, A. F. Preece, Y. Xu, & K. Gustafsson: Antisense inhibition of pig a1,3galactosyltransferase leads to a reduction in expression of the major target for human natural antibodies on pig vascular endothelial cells. Xenotransplantation 2, 143-7 (1995)

14. R. G. Spiro & V. D. Bhoyroo: Occurrence of a-D-galactosyl residues in the thyroglobulins from several species - localization in the saccharide chains of the complex carbohydrate units. J Biol Chem 259, 9859-66 (1984)

15. U. Galili, C. B. Basbaum, S. B. Shohet, J. Buehler, & B. A. Macher: Identification of erythrocyte Gala1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. J Biol Chem 262(10), 4683-8 (1987)

16. U. Galili & K. Swanson: Gene sequences suggest inactivation of a-1,3- galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 88, 7401-4 (1991)

17. U. Galili, E. A. Rachmilewitz, A. Peleg, & I. Flechner: A unique natural human IgG antibody with anti-a-galactosyl specificity. J Exp Med 160, 1519-31 (1984)

18. J. Wieslander, O. Månsson, E. Kallin, A. Gabrielli, H. Nowack, & R. Timpl: Specificity of human antibodies against Gal-a1-3Gal carbohydrate epitope and distinction from natural antibodies reacting with Gal-a-1-2Gal or Gal-a-1-4Gal. Glycoconjugate J 7, 85-100 (1990)

19. M. S. Sandrin & I. F. C. McKenzie: Gala(1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 141, 169-90 (1994)

20. M. W. Chopek, R. L. Simmons, & J. L. Platt: ABO incompatible renal transplantation: initial immunopathologic evaluation. Transplant Proc 19, 4553-4 (1987)

21. Schachter, H. and Roseman, S. In: The biochemistry of glycoproteins and proteoglycans. Ed. W. Lennarz, Plenum Press, New York, NY: , 85-160 (1980)

22. F. -i. Yamamoto, H. Clausen, T White, J. Marken, & S. -I. Hakomori: Molecular genetic basis of the histo-blood group ABO system. Nature 345, 229-33 (1990)

23. K. M. Strahan, F. Gu, A. F. Preece, I. Gustavsson, L. Andersson, & K. Gustafsson: cDNA sequence and chromosome localization of pig a1,3galactosyltransferase. Immunogenetics 41, 101-5 (1995)

24. M. S. Sandrin, P. L. Dabkowski, M. M. Henning, E. Mouhtouris, & I. F. C. McKenzie: Characterization of cDNA clones for porcine a1,3galactosyltransferase: the enzyme generating the Gal(a1,3)Gal epitope. Xenotransplantation 1, 81-8 (1994)

25. R. D. Larsen, V. P. Rajan, & J. F. Kukowska-Latallo: Isolation of a cDNA encoding a murine UDPgalactose:b-D- galactosyl-1,4-N-acetyl-D-glucosaminide a-1,3- galactosyltransferase: expres-sion cloning by gene transfer. Proc Natl Acad Sci USA 86, 8227-31 (1989)

26. D. H. Joziasse, J. H. Shaper, D. H. Van den Eijnden, A. J. Van Tunen, & N. L. Shaper: Bovine a1-3-Galactosyltransferase: isolation and charac-terization of a cDNA clone. J Biol Chem 264, 14290-7 (1989)

27. F. -i. Yamamoto & S. -I. Hakomori: Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions. J Biol Chem 265, 19257-62 (1990)

28. K. Gustafsson, K. Strahan, & A. Preece: a1,3Galactosyltransferase: a target for in vivo genetic manipulation in xenotransplantation. Immunol Rev 141, 59-70 (1994)

29. M. S. Sandrin, H. A. Vaughan, P. L Dabkowski, & I. F. C. McKenzie: Anti-pig IgM antibodies in human serum react predominantly with Gal(a1-3)Gal epitopes. Proc Natl Acad Sci USA 90, 11391-5 (1993)

30. R. D. Larsen, C. A. Rivera-Marrero, L. K. Ernst, R. D. Cummings, & J. B. Lowe: Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:b-D-Gal(1,4)-D-GlcNAc a(1,3)- galactosyltransferase cDNA. J Biol Chem 265, 7055-61 (1990)

31. D. H. Joziasse, J. H. Shaper, E. Wang Jabs, & N. L. Shaper: Characterization of an a1-3-galactosyltransferase homologue on human chromo-some 12 that is organized as a processed pseudogene. J Biol Chem 266, 6991-8 (1991)

32. U. Galili & P. Andrews: Suppression of a-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates. J Hum Evol 29, 433-42 (1995)

33. U. Galili, R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, & J. M. Griffis: Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56, 1730-7 (1988)

34. R. M. Hamadeh, G. A. Jarvis, U. Galili, R. E. Mandrell, P. Zhou, & J. M. Griffis: Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest 89, 1223-35 (1992)

35. J. L. Avila, M. Rojas, & U. Galili: Immunogenic Gala1-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol 142, 2828-34 (1989)

36. A. S. Couto, M. F. Gonclaves, W. Colli, & R. M. deLederkremer: The N-linked carbohydrate chain of the 85-kilodalton glycoprotein from Trypanosoma cruzi trypomastigotes contains sialyl, fucosyl and galactosyl (a1-3) galactose units. Mol Biochem Parasitol 39, 101-9 (1990)

37. I. C. Almeida, S. R. Milani, A. J. Gorin, & L. R. Travoassos: Complement mediated lysis of Trypanosoma cruzi trypomastigotes by human anti a-galactosyl antibodies. J Immunol 146, 2394-2401 (1991)

38. R. Geyer, H. Geyer, S. Strim, G. Hunsmann, J. Schneider, U. Dabrowski, & J. Dabrowski: Major oligosaccharides in the glycoprotein of Friend murine leukemia virus: Structure elucidation by one- and two-dimensional proton nuclear magnetic resonance and methylation analysis. Biochemistry 23, 5628-34 (1984)

39. P. M. Repik, J. M. Strizki, & U. Galili: Differential host-dependent expression of a-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. J Gen Virology 75, 1177-81 (1994)

40. Y. Takeuchi, C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, F. -L. Cosset, R. A. Weiss, & M. K. L. Collins: Sensitization of cells and retroviruses to human serum by alpha(1-3)galactosyltransferase. Nature 379, 85-8 (1996)

41. M. G. Michaels, J. P. McMichael, K. Brasky, S. Kalter, R. L. Peters, T. E. Starzl, & R. L. Simmons: Screening donors for xenotransplantation. The potential for xenozoonoses. Transplantation 57, 1462-5 (1994)

42. J. S. Allan: Xenotransplantation at a cross roads: prevention versus progress. Nat Med 2, 18-21 (1996)

43. L. A. Galli-Taliadoros, J. D. Sedgwick, S. A. Wood, & H. Korner: Gene knock-out technology: a methodological overview for the interested novice. J Immunol Meth 181, 1-15 (1995)

44. A. D. Thall, P. Maly, & J. B. Lowe: Oocyte Gala1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270, 21437-40 (1995)

45. R. D. Larsen, L. K Ernst, R. P. Nair, & J. B. Lowe: Molecular cloning, sequence, and expression of a human GDP-L-fucose: b-D-galactoside 2-L-fucosyltransferase cDNA that can form the H blood group antigen. Proc Natl Acad Sci USA 87, 6674-8 (1990)

46. R. W. Wagner: Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-5 (1994)

47. O. Heidenreich, S. -H. Kang, X. Xu, & M. Nerenberg: Application of antisense technology to therapeutics. Mol Med Today 1, 128-33 (1995)

48. T. Cech: RNA splicing: three themes with variations. Cell 34, 713-6 (1983)

49. S. Altman: Enzymatic cleavage of RNA by RNA. Angew Chem Int Ed Engl 29, 749-58 (1990)

50. A. C. Forster & R. H. Symons: Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49, 211-20 (1987)

51. H. W. Pley & K. M. Flaherty: Three-dimensional structure of a hammerhead ribozyme. Nature 372, 68-74 (1994)

52. S. Larsson, G. Hotchkiss, M. Andang, T. Nyholm, J. Inzunza, I. Jansson, & L. Ahrlund-Richter: Reduced b2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 22, 2242-8 (1994)

53. C. J. Pachuk, K. Yoon, K. Moelling, & L. R. Coney: Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 22, 301-7 (1994)

54. R. B. Denman, M. Smedman, W. Ju, R. Rubinstein, A. Potemska, & D. L. Miller: Ribozyme mediated degradation of b-amyloid peptide precursor mRNA in COS-7 cells. Nucleic Acids Res 22, 2375-82 (1994)

55. S. Efrat, M. Leiser, Y. -J. Wu, D. Fusco-DeMane, O. A. Emran, M. Surana, T. L. Jetton, M. A. Magnuson, G. Weir, & N. Fleischer: Ribozyme-mediated attenuation of pancreatic b-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc Natl Acad Sci USA 91, 2051-5 (1994)

[Table of Contents ] [Previous Section]